Evodiamine and rutaecarpine are the main active indoloquinazoline alkaloids of the herbal medicine, Evodia rutaecarpa, which is widely used for the treatment of hypertension, abdominal pain, angina pectoris, gastrointestinal disorder and headache.
DMD#57414

Introduction
Evodiamine and rutaecarpine are the main active indoloquinazoline alkaloids of the herbal medicine Evodia rutaecarpa, which has a variety of pharmacological actions including antithrombotic, anti-inflammatory, antianoxic, hypotensive and vasodilatory effects (Yu et al., 2013; Sheu, 1999) . In particular, the cytotoxicity of evodiamine and rutaecarpine on various human cancer cell lines has been extensively studied (Adams et al., 2007; Xu et al., 2006; Fei et al., 2003; Liao et al., 2005; Ogasawara at al., 2001) . It has been reported that evodiamine inhibited the proliferation of a wide variety of tumor cells by inducing the apoptosis via different mechanisms including caspase-dependent and -independent pathways, sphingomyelin pathway and PI3K/Akt/caspase, and Fas-DMD#57414 6 routes of rutaecarpine is the CYP1A-catalyzed oxidation to the metabolite 10-hydroxyrutaecarpine, which is excreted in the rat urine as a glucuronide conjugate (Jan et al., 2006) . Recently, evodiamine, another main active indoloquinazoline alkaloid present in Evodia rutaecarpa, was demonstrated to undergo similar cytochrome-P450 mediated oxidative biotransformation (Sun et al., 2012) . In addition to aromatic and aliphatic hydroxylation, other metabolic pathways including N-demethylation of evodiamine were observed (Sun et al., 2012) . Of particular interest in the metabolism pathways of rutaecarpine is the detection of 10-and 12-hydroxy metabolites of rutaecarpine (Ueng et al., 2005; Lee et al., 2006b) . 10-and 12-hydroxyrutaecarpine can undergo P450-mediated two-electron oxidations to form electrophilic para-and ortho-quinone imine intermediates respectively, which are capable of reacting with cellular proteins and other nucleophiles such as glutathione. In addition, as depicted in Fig. 1 , rutaecarpine and evodiamine are indoloquinazoline alkaloids containing a 3-alkylindole ring system which can potentially undergo P450-mediated dehydrogenation reactions to form an electrophilic 3-methyleneindolenine (3MEI) species. However, to date, no such reactive intermediates have been reported, and the bioactivation mechanism of the indoloquinazoline alkaloids remains unknown.
In the present study, we report the detection and identification of several GSH conjugates of evodiamine, derived from the addition of the sulfhydryl nucleophile to mono-hydroxyevodiamine, evodiamine and N-demethylated evodiamine. Similar conjugates were formed in the incubations of rutaecarpine. In addition, efforts are made to evaluate the relative contributions from individual P450 isoforms to formation of the GSH conjugates. These findings are of significance for understanding the relationship DMD#57414
Materials and Methods
Materials.
The following chemicals were purchased from Sigma-Aldrich (St.
Louis, MO): evodiamine (racemic), rutaecarpine, GSH, trichloroacetic acid and NADPH.
Pooled human liver microsomes and Supersomes TM containing cDNA-baculovirus-insect cell-expressed P450s (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4) were obtained from BD Gentest (Woburn, MA).
Formic acid, methanol, and acetonitrile were purchased from Fisher Scientific (Fair Lawn, NJ). All other commercially available reagents and solvents were of either analytical or HPLC grade.
In Vitro Metabolism. All incubations were performed at 37 °C in a water bath.
Pooled human liver microsomes and the human cDNA-expressed P450 isozymes were carefully thawed on ice prior to the experiment. Evodiamine or rutaecarpine (10 μ M and 50 μ M) was mixed with human liver microsomal proteins (1 mg/ml) in 100 mM potassium phosphate buffer (pH 7.4) supplemented with 1 mM GSH. The total incubation volume was 1 mL. After 3 min pre-incubation at 37 °C, the incubation reactions were initiated by the addition of 1 mM NADPH. . For a full scan, the automatic gain control was set at 5.0 x 10 8 , maximum ion time was 100 ms, and the number of microscans was set at 3. For MS n scanning, the automatic gain control was set at 1.0 x 10 8 , maximum ion time was 400 ms, and the number of microscans was set at 2. For data-dependent scanning, the default charge state was 1, default isolation width was 2.0, and normalized collision energy was 35. Polarity switching was applied to acquire full scan and data-dependent MS n spectra in both positive and negative ion mode. Fourier transform MS (FTMS) was set up to acquire high resolution full scan MS in the positive ion mode.
Complete profiling of reactive metabolites was also carried out using the precursor ion (PI)-enhanced product ion (EPI) method previously described (Wen et al, 2008b) . Briefly, the PI scan of m/z 272 was run in the negative mode with 0.2 Da step size, 5 ms pause between mass ranges and 2 s scan rate or 50 ms dwell. The TurboIonSpray ® ion source conditions were optimized and set as follows: curtain gas = 35, collision gas = medium, ionspray voltage = -4500, temperature = 500. Information dependent acquisition was used to trigger acquisition of EPI spectra. The EPI scans were run in the positive mode at a scan range for daughter ions from m/z 100 to 1000. Data were processed using Analyst 4.1 software (Applied Biosystems, Foster City, CA). The Shimadzu HPLC system was coupled with an Agilent Eclipse XDB-Phenyl C18 column Metabolite Isolation and NMR Characterization. Human liver microsomal incubations with evodiamine (50 μ M) were performed as described above on a 50 mL scale. Trichloroacetic acid (10%) was added to terminate the reaction after 60 min incubation. Samples were centrifuged at 10,000 g for 15 min at 4 °C to pellet the precipitated proteins, and supernatants were concentrated by solid phase extraction as described above. The major GSH conjugate EM1 was therefore isolated from the cleaned and concentrated reaction mixture. Separation was achieved using a Polaris ® C18 column 
Results
Characterization of GSH conjugates in Human Liver Microsomes. For the LC/MS/MS analysis of GSH conjugates, samples generated from incubations with human liver microsomes were desalted and concentrated by solid-phase extractions, and resulting samples were subjected to both data-dependent LC-MS n scanning and PI-EPI experiments described above. The metabolic profiles of evodiamine and rutaecarpine in human liver microsomes showed several GSH conjugates EM1-4 and RM1-3, respectively ( Fig. 2 ). There were several other components in the metabolic profile of evodiamine, for instance, the peaks eluted at 12.6, 14.2 and 14.9 min ( (Fig. 5C ). In particular, the fragment ion at m/z 192 suggested that both mono-hydroxylation and glutathione conjugation occurred on the 3-alkylindole structural motif of evodiamine (Fig. 5C) . A proposed structure for EM3, which is consistent with the CID cleavage, is shown in Figure 5 .
The minor adduct EM4 revealed a molecular ion [M + H]
+ of m/z 595, suggesting DMD#57414 adduct with attachment of the sulfhydryl group to rutaecarpine (Supplemental Figure 4) .
Fragmentation of RM1 molecular ions resulted in a major product ion at m/z 286 derived from a neutral loss of GSH (307 Da) and afforded a protonated GSH product ion at m/z 308. Similar to evodiamine GSH adducts EM1 and EM4, these data suggested that RM1
is an aliphatic and/or benzylic thioether conjugate (Baillie and Davis, 1993) . The product ions at m/z 464 and 518 were derived from neutral loss of 129 and 75 Da, corresponding to elimination of the pyroglutamate and glycine of GSH, respectively (Supplemental are aromatic thioether conjugates with addition of the sulfhydryl moiety to the mono-and di-hydroxylated metabolites of rutaecarpine, respectively.
Formation of GSH conjugates with Recombinant P450s.
To investigate the roles of individual human P450 isozymes in the bioactivation of evodiamine and rutaecarpine, incubations were carried out with insect cell-expressed recombinant P450s.
The rates of metabolite formation obtained from individual incubations with recombinant P450 enzymes were multiplied by the mean specific content of the corresponding P450 enzyme in human liver microsomes to obtain the normalized reaction rates for each P450 enzyme (Rodrigues, 1999, Supplemental Table 1 ). After normalization for the relative hepatic abundance of P450 isozymes, CYP3A4 was the predominant enzyme in the formation of the major GSH conjugate EM1 in incubations of evodiamine (Fig. 8A ).
Only trace amounts or no EM1 were detected in incubations with other P450 enzymes including CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP2E1. Similarly, formation of EM2, EM3 and EM4 was predominantly carried out by CYP3A4 (Fig. 8A ). CYP1A2 and CYP2C19 also catalyzed EM2 formation, and the levels were approximately 19% and 10% of those formed by CYP3A4, respectively.
Similar contributions from CYP1A2 and CYP2C19 were observed with formation of EM3. For rutaecarpine GSH adducts, CYP3A4 was also the predominant enzyme in the formation of RM1-3 (Fig. 8B ). Only trace amounts or no RM1 were detected in incubations with other P450 enzymes. In contrast, CYP2D6 contributed significantly to This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 8B) . These results suggested that CYP3A4 is the major P450 enzyme involved in the formation of EM1, EM4 and RM1 presumably via a 3MEI intermediate via dehydrogenation mechanism (Scheme 1).
CYP3A4 Inactivation Kinetics of Evodiamine. Preincubation of evodiamine
with human liver microsomes showed that CYP3A4 was inactivated in a time-and concentration-dependent manner (Fig. 9A) . The observed first-order rate constants (k obs )
of the inactivation reaction, at a specific evodiamine concentration, were calculated from the slopes of these lines. The hyperbolic plot of k obs versus evodiamine concentrations was shown in Fig. 9B , from which rate constants were obtained. respectively. These findings are of importance to understand the bioactivation pathways of indoloquinazoline alkaloids and potential links to its mechanism of toxicity and drugdrug interactions.
Bioactivation of evodiamine was found to be mediated likely via multiple mechanisms by human liver microsomes. For the major benzylic thioether adduct EM1, GSH conjugation occurred specifically at C-8 of the aliphatic ring of evodiamine which was confirmed by LC/MS n and NMR analysis. A proposed mechanism for the formation of evodiamine GSH adducts EM1 and EM4 is depicted in Scheme 1. Upon an initial hydrogen atom abstraction from the 3-methylene position of the indole ring, evodiamine undergoes dehydrogenation reactions to generate a reactive 3MEI species. Such dehydrogenation mechanisms have been proposed for the bioactivation of several 3-alkylindole-containing compounds, such as 3-methylindole (Skiles and Yost, 1996; Thornton-Manning et al., 1996; Yan et al., 2007) , zafirlukast (Kassahun et al., 2005) , and more recently, a TNF-α inhibitor SPD-304 (Sun and Yost, 2008) . In this mechanism, the This article has not been copyedited and formatted. The final version may differ from this version. where an aliphatic hydroxyl metabolite of evodiamine was detected in human liver microsomes (Sun et al., 2012) . Alternatively, hydration of 3MEI would lead to formation of the alcohol metabolite 8-hydroxyevodiamine and vice versa (Scheme 1). These findings suggested that 3-alkylindole moieties are potential toxicophores through the generation of highly eletrophilic 3MEI species by dehydrogenation reactions. However, further investigation is needed to confirm such proposed mechanisms using techniques including stable isotope labeling and
18
O incorporation (Skiles and Yost, 1996) .
Formation of EM2 and EM3 was presumably via a quinone imine intermediate.
Upon initial hydroxylation by P450 enzymes, 10-or 12-hydroxyevodiamine metabolite undergoes an overall two-electron oxidation to yield their respective iminoquinone species, which can be trapped by GSH via a nucleophilic addition to generate the GSH adducts EM2 and EM3, respectively (Scheme 1). Such a two-step oxidation mechanism has been proposed for the bioactivation of 3-methylindole (Yan et al., 2007) and other compounds forming p-aminophenol metabolites, such as diclofenac (Shen et al., 1999; Poon et al., 2001) , and lumiracoxib (Li et al., 2008; Kang et al., 2009 ). This was in parallel with previous studies whereas such hydroxylated metabolites of evodiamine and rutaecarpine were detected in liver microsomes (Ueng et al., 2005; Ueng et al., 2006; Sun et al., 2012) . The reactive iminoquinone species would covalently modify nucleophilic DMD#57414 residues of cellular proteins and/or P450 enzymes leading to toxicity and enzyme inactivation. However, apart from these oxidative activation pathways, it is noteworthy that the role of phase II metabolism (eg. glucuronidation, sulfation) of the hydroxylated metabolites, e.g. 10-or 12-hydroxyrutaecarpine, remains to be elucidated (Lee et al., 2005; Jan et al., 2006) , and phase II conjugation of the hydroxylated metabolites would serve as an alternative clearance and/or detoxification pathway prior to further oxidations.
The NADPH-dependent formation of GSH conjugates indicated that one or more P450 enzymes were involved in the generation of reactive intermediates of evodiamine and rutaecarpine by human liver microsomes. Experiments with recombinant P450 enzymes revealed that formation of benzylic thioether GSH conjugates EM1, EM4
and RM1 was predominantly mediated by CYP3A4, suggesting that CYP3A4 is the predominant P450 isozyme involved in the dehydrogenation mechanism. Formation of EM2 and EM3 was primarily carried out by CYP3A4 and, to a lesser extent, CYP1A2
and CYP2C19 respectively. It was noteworthy that CYP2D6 contributed significantly to formation of rutaecarpine GSH conjugates RM2 and RM3, with levels of approximately 39% and 37% of those formed by CYP3A4 respectively. This was in line with the previous findings that CYP2D6 played a significant role in rutaecarpine 10-and 12-hydroxylations (Ueng et et al., 2006) , which are the initial steps leading to formation of the iminoquinone species and corresponding GSH conjugates.
In conclusion, we found that the 3-alkylindole moiety in the indoloquinazoline alkaloids evodiamine and rutaecarpine is a potential toxicophore through the generation of highly eletrophilic 3MEI species by P450-mediated dehydrogenation reactions.
This article has not been copyedited and formatted. The final version may differ from this version. CYP3A4 is the predominant P450 isozyme involved in the dehydrogenation mechanism, whereas CYP2D6 also played a significantly role in oxidation and bioactivation of rutaecarpine via formation of iminoquinone species. It is our hypothesis that 3MEI or another reactive intermediate was a mechanism-based inactivator of CYP3A4. In summary, findings from the current study are of significance in understanding the bioactivation mechanisms of indoloquinazoline alkaloids and dehydrogenation of evodiamine and rutaecarpine may cause toxicities through formation of electrophilic intermediates and lead to drug-drug interactions.
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